Aadi Bioscience (NASDAQ:AADI – Get Free Report) and Actinium Pharmaceuticals (NYSE:ATNM – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, profitability, valuation and earnings.
Insider and Institutional Ownership
52.1% of Aadi Bioscience shares are owned by institutional investors. Comparatively, 27.5% of Actinium Pharmaceuticals shares are owned by institutional investors. 37.3% of Aadi Bioscience shares are owned by insiders. Comparatively, 0.6% of Actinium Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Profitability
This table compares Aadi Bioscience and Actinium Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Aadi Bioscience | -246.06% | -71.87% | -57.28% |
| Actinium Pharmaceuticals | N/A | -100.85% | -47.89% |
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Aadi Bioscience | $25.07 million | 2.87 | -$65.76 million | ($2.35) | -1.24 |
| Actinium Pharmaceuticals | $90,000.00 | 461.01 | -$48.82 million | ($1.10) | -1.21 |
Actinium Pharmaceuticals has lower revenue, but higher earnings than Aadi Bioscience. Aadi Bioscience is trading at a lower price-to-earnings ratio than Actinium Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Aadi Bioscience has a beta of 0.68, suggesting that its stock price is 32% less volatile than the S&P 500. Comparatively, Actinium Pharmaceuticals has a beta of -0.3, suggesting that its stock price is 130% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current ratings and target prices for Aadi Bioscience and Actinium Pharmaceuticals, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Aadi Bioscience | 0 | 0 | 0 | 0 | 0.00 |
| Actinium Pharmaceuticals | 0 | 0 | 1 | 0 | 3.00 |
Actinium Pharmaceuticals has a consensus target price of $4.00, indicating a potential upside of 200.75%. Given Actinium Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts plainly believe Actinium Pharmaceuticals is more favorable than Aadi Bioscience.
Summary
Actinium Pharmaceuticals beats Aadi Bioscience on 9 of the 14 factors compared between the two stocks.
About Aadi Bioscience
Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.
About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company’s research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.
Receive News & Ratings for Aadi Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aadi Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
